Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Friday, November 20, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Merck announced that the TroFuse-015 trial evaluating Sacituzumab Tirumotecan (Sac-TMT) met its primary endpoint of overall survival (OS). This trial focused on patients with third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. The results indicate a potential benefit for this patient population.
Market Sentiment Analysis
POSITIVE FACTORS
TroFuse-015 trial met its primary endpoint.
Sacituzumab Tirumotecan shows promise for patients.
Overall survival (OS) was successfully evaluated.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
2.8%
average across 15 past catalysts
Lead asset
MK-8527
Phase 1 · HIV Pre-exposure Prophylaxis
Full Press Release Details
RAHWAY, N.J.--(BUSINESS WIRE)--TroFuse-015 Evaluating Sac-TMT Met Primary Endpoint of OS in 3rd-Line or Later Locally Adv. Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Frequently Asked Questions
What is the TroFuse-015 trial about?
The TroFuse-015 trial evaluates Sacituzumab Tirumotecan in advanced gastroesophageal cancer.
What was the primary endpoint of the trial?
The primary endpoint was overall survival (OS) in patients.
Who conducted the TroFuse-015 trial?
The trial was conducted by Merck.
What type of cancer was studied in the trial?
The trial focused on gastroesophageal adenocarcinoma.